News & Updates

In the treatment of patients with methicillin-susceptible S aureus (MSSA)-associated infective endocarditis, the cefazolin is as good as cloxacillin, with similar mortality and relapse rates, according to a study.

In patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, adding pembrolizumab to concurrent chemoradiotherapy (cCRT) significantly improves progression-free survival (PFS) vs cCRT alone, according to results of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study presented at European Society for Medical Oncology Congress 2023 (ESMO 2023).

Depression levels among adults appear to be positively associated with respiratory symptoms, asthma, and chronic obstructive pulmonary disease (COPD), according to a study.

Patients with nonalcoholic fatty liver disease (NAFLD) tend to have higher rates of irritable bowel syndrome (IBS) symptoms, depression, and anxiety, suggests a study.

In the treatment of patients with advanced or recurrent endometrial carcinoma, adding the PD-L1 inhibitor atezolizumab to chemotherapy helps lower the risk of progression or death, according to the phase III AtTEnd trial.

Consumption of sugar-sweetened beverages appears to raise the risk of colorectal cancer (CRC), independent of CRC mortality, results of a meta-analysis have shown.

In the phase III EV-302/KEYNOTE-A39 trial, the combination of enfortumab vedotin and pembrolizumab (EV+P) had a significant survival advantage over chemotherapy in the first-line treatment of patients with locally advanced metastatic urothelial carcinoma (la/mUC).